A phase 1/2a study to evaluate the dose, safety, tolerability, and efficacy of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in subjects with peritoneal carcinomatosis from colorectal carcinoma following hyperthermic intraperitoneal chemotherapy

2024-511853-23-00 Human pharmacology (Phase I) - First administration to humans Ended

Start 12 May 2020 · End 23 Apr 2025 · Status Ended · 2 EU/EEA countries · 2 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 54
Countries 2
Sites 2

Peritoneal carcinomatosis (PC) from colorectal carcinoma

Key facts

Sponsor
Oncoinvent ASA
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
12 May 2020 → 23 Apr 2025
Decision date (initial)
2024-09-27
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511853-23-00
EudraCT number
2018-002803-33
ClinicalTrials.gov
NCT03732781

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Peritoneal carcinomatosis (PC) from colorectal carcinoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oncoinvent ASA

Sponsor organisation
Oncoinvent ASA
Address
Gullhaugveien 7
City
Oslo
Postcode
0484
Country
Norway

Scientific contact point

Organisation
Oncoinvent ASA
Contact name
Information Desk

Public contact point

Organisation
Oncoinvent ASA
Contact name
Information Desk

Locations

2 EU/EEA countries · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Norway Ended 40 1
Sweden Ended 14 1
Rest of world 0

Investigational sites

Norway

1 site · Ended
Oslo University Hospital HF
Surgical Oncology, Montebello, Ullernchausséen 70, Oslo

Sweden

1 site · Ended
Uppsala University Hospital
Kirurgiska kliniken, Akademiska Sjukhuset, 751 85, Uppsala

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Norway 2020-05-12 2025-05-14 2020-05-14 2023-11-30
Sweden 2020-10-22 2025-04-23 2020-12-07 2023-11-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-29 Norway Acceptable
2024-09-23
2024-09-23
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-09 Norway Acceptable
2024-09-23
2025-05-09